The results of a meta-analysis indicate that GLP-1RAs can reduce major adverse cardiovascular events (MACE) such as cardiovascular death, stroke, or myocardial infarction, as well as hospital admissions for heart failure and all-cause mortality, in patients with T2D [44]
Continuous Support and Monitoring: We provide regular follow-up appointments to track your progress, address concerns, and optimize your treatment plan
Low Dose Semaglutide Does Not Impair Skeletal Muscle Function in ZSF1 Obese Rats While GLP-1RAs, including semaglutide, have been linked to loss of lean muscle mass in obesity treatment 80,81 , the long-term clinical implications of this effect on quality of life and morbidity, particularly in the context of HFpEF 82 , remain unclear
Precedence Research expects this space to grow at an average annual pace of nearly 25% through 2035, so it's not surprising that new competitors are emerging for a bite at this proven profit opportunity
By End User Analysis Hospitals: Hospitals held the largest market share in 2024, driven by the rising incidence of diabetes, obesity, and associated diseases
When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
